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Stage IIIA endometrial cancer includes patients with serosal or adnexal invasion and patients with positive peritoneal cytology only. In
this study, we assessed the impact of peritoneal cytology on endometrial cancer survival. All endometrial cancer patients receiving
surgery and radiotherapy at the Geneva University Hospitals between 1980 and 1993 were included. Stage lllA cancers were
categorised into ‘cytological’ stage lllA (only positive peritoneal cytology) and ‘histological’ stage lllA (serosal or adnexal infiltration).
Survival rates were analysed by Kaplan–Meier method and compared using log-rank test. The prognostic importance of peritoneal
cytology was analysed by multivariate regression analysis. This study included 170 endometrial cancers (112 stage I, 17 cytological
stage IIIA, 18 histological stage IIIA, 9 stage lllBþ). Disease-specific survival of cytological stage IIIA was not different from stage I (94
vs 88% respectively, P¼0.5) but better than histological stage IIIA (94 vs 51% respectively, Po0.01). Histological stage IIIA patients
were at increased risk to die from cancer compared to stage I patients (HR 2.7, 95% CI 1.0–7.7), while cytological stage IIIA patients
were not (HR 0.3, 95% CI 0.3–2.0). Cytological stage lllA endometrial cancer has similar prognosis as stage l and better prognosis
than histological stage IIIA. Additional research, definitively separating stage and cytology is warranted.
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Endometrial cancer is the most common genital tract malignancy in
Western countries (Grady and Ernster, 1996; Burke et al, 1997;
Parkin et al, 1997; Greenlee et al, 2000). The long-term survival of
patients with endometrial cancer is related to the stage at diagnosis.
Disease-specific 5-year survival for tumours confined to the uterus
is over 80%, but decreases to approximately 40% for tumours
invading the serosa, the fallopian tube or the ovary (AJCC, 2002).
Before 1988, endometrial cancer was staged clinically (Interna-
tional Federation of Gynaecology & Obstetrics, FIGO 1971). This
staging system was based on the fractional biopsy of the
endometrium, the size of the uterine cavity and physical
examination. The clinical system was abandoned because newly
accumulated data from surgical staging reports, among others
including depth of myometrial invasion, allowed stratification. A
new surgical staging system was approved at the 1988 FIGO
meeting (Grady and Ernster, 1996; Burke et al., 1997; FIGO, 2000;
AJCC, 2002). In addition to pathological extension, the result of
cytology obtained by peritoneal washings became an important
determinant of staging. In particular, stage l patients with positive
peritoneal cytology were upstaged to stage lllA (Konski et al, 1988).
Stage IIIA therefore covers both patients with only positive
peritoneal cytology and patients with macroscopic/histological
invasion of serosa or adnexal tissues.
As some studies have suggested that cytology is an important
prognostic factor, while others did not (Grimshaw et al, 1990;
Morrow et al, 1991; Kadar et al, 1992; Obermair et al, 2001; Preyer
et al, 2002; Kasamatsu et al, 2003), the value of peritoneal cytology
in the staging of endometrial cancer is still controversial
(Kasamatsu et al, 2003). In this study, we evaluated the impact
of positive peritoneal cytology on the survival of patients operated
for endometrial carcinoma and treated with adjuvant brachyther-
apy and/or external radiotherapy.
METHODS
Patients
The current study included women who received surgery followed
by adjuvant external radiotherapy and/or brachytherapy for
endometrial cancer between 1980 and 1993 at the departments of
Gynaecology and Radiation Oncology of the Geneva University
Hospitals (n¼295). We excluded patients with stage I or stage II
endometrial cancer without peritoneal cytology assessment
(n¼111), women with previous malignancy occurring within 5
years prior to the diagnosis of endometrial cancer (n¼2), or
patients who were not resident in the canton (n¼12). The final
study population included 170 patients. According to the Geneva
cancer registry, these women represented approximately 50% of all
endometrial cancer patients treated in the public sector during the
period considered. Received 20 May 2003; accepted 6 October 2003
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lPeritoneal washing was performed by either collecting liquid
present in the peritoneal cavity, or by rinsing the cavity with
100cm
3 of physiological saline. The liquid was centrifuged and
assessed for the presence of malignant cells. Surgical treatment
generally included hysterectomy and oophorosalpingectomy,
except for three patients (o2%) who received only simple
hysterectomy. A total of 12 patients (7%) underwent lymph node
dissection. All surgical procedures were followed by external
radiotherapy and/or brachytherapy.
Variables
Histologic type and differentiation of the endometrial tumours
were coded according to the International Classification of
Diseases for Oncology (World Health Organization, 1990). A
patient was considered to have positive peritoneal cytology if
adenocarcinoma cells were detected, regardless of the number of
cancer cells. Stages were coded according to the 1988 FIGO staging
system: stage I, tumour confined to uterus; stage II, tumour
invading cervix; stage IIIA, tumour associated with positive
peritoneal cytology or macroscopic or histological involvement
of serosa or adnexa and stage IIIBþ, tumour invading vagina,
mucosa of bladder/bowel, regional lymph node or distant
metastases. For the purpose of the present study, stage lllA
cancers were further categorised as: ‘cytological’ stage lllA defined
as cases with only positive peritoneal cytology and ‘histological’
stage lllA defined as cases with histological or macroscopic
infiltration of serosa or adnexal tissues.
Other variables of interest were: age at diagnosis (o50, 50–69,
X70 years), period of diagnosis (1980–87, 1988–93), differentia-
tion (good, moderate, poor, unknown), degree of myometrial
invasion (o50%, X50%), type of surgery (hysterectomy and
oophorosalpingectomy with and without lymphadenectomy), and
type of radiotherapy (external with brachytherapy, external only,
brachytherapy only).
Data on survival and follow-up were derived from the Geneva
cancer registry and included vital status and date of death or
departure from the canton (regularly and systematically obtained
from the Cantonal Population Office) and cause of death (retrieved
from medical files).
Statistical analyses
The 5-year overall and disease-specific survival rates were
calculated. Disease-specific survival was calculated considering
death from endometrial cancer only. Survival curves were obtained
by Kaplan–Meier method and were compared by nonparametric
survival analyses using log-rank test. The effect of peritoneal
cytology on endometrial cancer mortality was analysed by
multivariate Cox’s proportional-hazards regression analysis, tak-
ing into account other variables significantly linked to survival.
Analyses were performed using SPSS (Hull and Nie, 1995).
Differences were considered statistically significant at Po0.05.
RESULTS
Of the 170 endometrial cancer patients included in the study, 112
were diagnosed as stage I, 14 as stage II, 17 as cytological stage IIIA,
18 as histological stage IIIA, and nine were diagnosed as stage
IIIBþ. If peritoneal cytology had not been incorporated in the
Table 1 Characteristics of 170 endometrial cancer patients according to stage
Stage I
(n¼112) n (%)
Stage II
(n¼14) n (%)
Stage IIIA cyt
(n¼17) n (%)
Stage IIIA hist
(n¼18) n (%)
Stage IIIB+(n¼9)
n (%)
Mean age (range) years 64 (33–81) 66 (55–78) 66 (51–81) 65 (42–90) 65 (37–77)
Age category (years)
o50 7 (6) — — 2 (11) 1 (11)
50–69 71 (63) 10 (71) 12 (71) 10 (56) 4 (44)
70+ 34 (31) 4 (29) 5 (29) 6 (33) 4 (44)
Period of diagnosis
1980–1987 65 (58) 4 (29) 5 (29) 5 (28) 7 (78)
1988–1993 47 (42) 10 (71) 12 (71) 13 (72) 2 (22)
Invasion of myometrium
o50% 70 (63) 4 (29) 8 (47) 5 (28) 4 (44)
X50% 42 (37) 10 (71) 9 (53) 13 (72) 5 (56)
Differentiation
Good 67 (60) 5 (45) 8 (57) 6 (38) 2 (22)
Moderate 30 (27) 4 (36) 3 (21) 4 (25) 4 (44)
Poor 15 (13) 2 (18) 3 (21) 6 (38) 3 (33)
Unknown — 3 3 2 —
Surgical treatment
Hysterectomy 3 (3) — — — —
Hysterectomy+unilat/Bilateral
annexectomy Idem plus lymphadenectomy
105 (94) 13 (93) 16 (94) 17 (94) 4 (44)
4 (3) 1 (7) 1 (6) 1 (6) 5 (56)
Radiotherapy
External and brachy 46 (42) 11 (92) 11 (58) 15 (83) 7 (78)
External only 8 (7) — 3 (21) 3 (17) 2 (22)
Brachy only 56 (51) 1 (8) 3 (21) — —
Unknown 2 2 — — —
Stage I¼tumour confined to uterus; stage II¼tumour invading cervix; stage IIIA cyt¼positive peritoneal cytology; stage IIIA hist¼histological involvement of serosa or adnexa;
stage IIIB+¼tumour invading vagina, mucosa of bladder/bowel, regional lymph node or distant metastases.
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lstaging of the endometrial cancers, 15 of the 17 cytological stage IIIA
tumours would have been classified as stage I and two as stage II.
Table 1 presents the characteristics of these 170 patients
according to stage of endometrial cancer. The mean age of the
patients was 64.7 years and was similar for the different stages.
Compared to histological stage IIIA tumours, cytological stage IIIA
tumours invaded the myometrium to a lesser extent, were better
differentiated and received less aggressive radiotherapy.
The median duration of follow-up was 126 months and 14
patients (8%) were lost to follow-up. Table 2 presents overall and
disease-specific 5-year survival rates per stage. Figure 1 presents
disease-specific survival curves for stage I, cytological stage IIIA
and histological stage IIIA endometrial cancer. The disease specific
5-year survival of patients with cytological stage IIIA tumours was
not significantly different from that of patients with stage I
tumours (94 vs 88% respectively, log-rank test: P¼0.5). In
contrast, the 5-year disease-specific survival of patients with
histological stage IIIA tumours was significantly worse (51 vs 94%
for histological vs cytological stage IIIA cancers, log-rank test:
Po0.01). A similar pattern was observed when considering the
overall survival rates accounting for all deaths, including death
from other causes than endometrial cancer.
After adjustment for factors significantly linked to survival from
endometrial cancer (i.e. age, tumour differentiation and type of
radiotherapy) as shown in Table 3, the risk to die from endometrial
cancer was still not significantly different in patients with
cytological stage IIIA compared with patients with stage I cancer
(HR 0.3, 95% CI 0.3–2.0). Compared to stage I, patients with stage
II, histological IIIA, and IIIBþ tumours were at respectively 3.2-
fold (95% CI 1.2–8.6), 2.7-fold (95% CI 1.0–7.7) and 3.5-fold (95%
CI 1.2–10.4) increased risk to die from their endometrial cancer.
The results were not modified when excluding the two patients in
the cytological stage IIIA category who had cervical invasion (i.e.
who would have been staged as stage II in the absence of positive
peritoneal cytology).
DISCUSSION
This study is the first to compare the prognosis of patients with
stage I, cytological stage IIIA, and histological stage IIIA
endometrial cancer in the same patient population. It suggests
that positive peritoneal cytology is not an independent prognostic
factor in patients with endometrial cancer treated with surgery and
radiotherapy. Irradiated women with only positive cytology
(cytological stage IIIA) had the same prognosis as women with
endometrial cancer confined to the uterus (stage I) and a much
better prognosis than women with histological stage IIIA cancer.
However, our study has several limitations: 111 women had no
peritoneal cytology and were therefore excluded, patients were
selected for inclusion in the study on the basis of administration of
radiotherapy, and the study has a relatively low statistical power
due to the limited number of patients included. Nonetheless, the
lack of significant survival difference between the stage I and
cytological stage IIIA groups suggest that the FIGO classification
system classifies patients with positive peritoneal cytology into an
inappropriately high-risk category. However, this finding might
also be explained by a disproportionate benefit derived from
radiotherapy in patients with positive peritoneal cytology.
Table 4 shows that similarly high survival rates (88–94% 3–5
year survival) in women with stage I and cytological stage IIIA
cancer have been observed in series where, as in our study, the
large majority of cytological stage IIIA patients underwent either
pelvic radiotherapy or total pelvic lymphadenectomy (Kadar et al,
1992; Kasamatsu et al, 2003). In contrast, the relatively poor results
reported by other investigators (64–67% 3–5 year survival) in
cytological stage IIIA patients might be explained by the fact that
in these studies, only a minority of patients received treatment to
pelvic lymph nodes (Morrow et al, 1991; Obermair et al, 2001;
Preyer et al, 2002). Pelvic radiotherapy or lymphadenectomy might
be especially important for patients with positive peritoneal
cytology, as it has been shown by Morrow et al (1991) that the
presence of positive peritoneal cytology increases the risk of para-
aortic lymph node invasion (15 vs 4%), and by inference increases
the likelihood of pelvic node involvement.
Table 2 Observed and disease-specific 5-year survival after endometrial
cancer according to stage
n
Number of
endometrial
cancer
deaths
Median
follow-up
(days)
Overall
5-year
survival
a (%)
Disease
specific
5-year
survival
b (%)
Stage I 112 14 1825 85 88
Stage II 14 8 1176 36 43
Stage III cyt 17 1 1825 94 94
Stage IIIA hist 18 8 1048 44 51
Stage IIIB + 9 5 1224 44 44
Stage I¼tumour confined to uterus; stage II¼tumour invading cervix; stage IIIA
cyt¼positive peritoneal cytology; Stage IIIA hist¼histological involvement of serosa
or adnexa; stage IIIB+¼tumour invading vagina, mucosa of bladder/bowel, regional
lymph node or distant metastases.
aAll cases of death.
bDeath from endometrial
cancer.
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Figure 1 Disease-specific survival curves of endometrial cancer for the
stages I, cytological IIIA and histological IIIA. Stage I¼tumour confined to
uterus; stage IIIA cyt¼positive peritoneal cytology; stage IIIA
hist¼histological involvement of serosa or adnexa. Log-rank test of
comparison of survival of stage I vs cytological stage IIIA: P¼0.5; log-rank
test of comparison of survival of cytological stage IIIA vs stage histological
IIIA: P¼0.008.
Table 3 Hazard ratio
a of death from endometrial cancer according to
stage
HR
a 95% CI
Stage I 1
b
Stage II 3.2* 1.2–8.6
Stage IIIA cytological 0.3 0.3–2.0
Stage IIIA histological 2.7
c 1.0–7.7
Stage IIIB and more 3.5* 1.2–10.4
aHazard ratio are derived from Cox model adjusted for age, tumour differentiation
and type of radiotherapy (external radiation therapy, brachytherapy or both).
breference category.
cP borderline significant (0.057). *Po0.05. Stage I¼tumour
confined to uterus; stage II¼tumour invading cervix; stage IIIA cyt¼positive
peritoneal cytology; Stage IIIA hist¼histological involvement of serosa or adnexa;
stage IIIB+¼tumour invading vagina, mucosa of bladder/bowel, regional lymph node
or distant metastases.
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lThe proportion of cytological stage IIIA cancer patients with
cervical involvement is unknown in the majority of studies, except
for the study of Kasamatsu et al and ours, in which the proportions
of cytological stage IIIA patients with cervical involvement were
relatively low (0 and 12%, respectively). As cervical involvement is
known to affect the survival negatively, a higher proportion of
cytological stage IIIA patients with cervical involvement might
explain unfavourable survival rates. Therefore, the unknown
proportions of patients with cervical involvement complicate
interpretation of outcomes and impair comparison between the
different studies.
In conclusion, this study found comparable survival rates for
patients with cytological IIIA and stage I endometrial cancer,
which were significantly superior to that of patients with
histological stage IIIA endometrial cancer. Because all studies,
including ours, have important shortcomings, no definitive
conclusion on the importance of positive peritoneal cytology can
be drawn and therefore, additional research is warranted. We
strongly recommend that stage and cytology be separated in future
studies, in order to better define the impact of peritoneal cytology
on outcome of endometrial cancer.
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Preyer et al (2002) — 64
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Kadar et al (1992) 93
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